Shots:
- Alteogen has entered into an exclusive license agreement with a global pharmaceutical company to develop & commercialize a SC formulation of a biologic product utilizing ALT-B4 (berahyaluronidase alfa)
- As per the deal, the company will acquire exclusive global rights to the SC formulation of a biologic product. In exchange, Alteogen will receive ~$365M, incl. an upfront plus development, regulatory & sales milestone payments, with sale-based royalties
- ALT-B4 is a human recombinant hyaluronidase enzyme developed using Alteogen’s Hybrozyme tech. It temporarily hydrolyzes hyaluronan in the extracellular matrix to facilitate the large-volume SC delivery of drugs that are normally administered as IV
Ref: PRnewswire | Image: Alteogen | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
